Health Trials

Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients

ConditionsThrombosis, VenousCancerCatheter Complications
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences

About this trial

To evaluate the efficacy and safety of edoxaban in the prevention of tumor catheter-related thrombosis (CVC/PICC) in high-risk patients

Eligibility criteria

Qualifiers

Age≥18.

Cancer patients with a catheter-related thrombus risk prediction model score ≥ 19.6.

ECOG score≤2.

Expected survival period over 6 months.

Disqualifiers

Unknown location of the primary tumor.

Allergy to the active ingredient of edoxaban tablets or other excipients.

There is clinically significant active bleeding.

Platelet <50×109/L.

Trial design

Treatments tested in this trial

  • Edoxaban

Treatment groups

366 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Lead sponsor

Source ClinicalTrials.gov